Literature DB >> 14963349

Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.

Matthias May1, Christian Helke, Thomas Nitzke, Horst Vogler, Bernd Hoschke.   

Abstract

INTRODUCTION: The aim of this study was to establish to what extent the survival rates of muscle-invasive bladder carcinoma are influenced by the tumor stage at initial presentation. PATIENTS AND METHODS: This study examined the clinical course of 230 patients who underwent radical cystectomy for bladder carcinoma from 1992 to 2002. The patients were divided into three groups according to the histological results of the initial and final transurethral tumor resection (TURB). In group 1 (n = 41) radical cystectomy was carried out for a superficial bladder carcinoma which had a high likelihood of progressing. Group 2 (n = 57) consisted of patients who displayed a superficial tumor stage when they first presented and developed progressive muscle-invasive bladder carcinoma under conservative treatment. Group 3 (n = 132) was made up of patients who were already at the muscle-invasive tumor stage in the course of primary TURB. The histopathological characteristics of all transurethral tumor resections and radical cystectomy were recorded. Progression-free survival and overall survival in the three groups were then compared.
RESULTS: The average patient age when cystectomy was carried out was 63.9 (35-80) years and the average follow-up period was 38 months. An average of 2.3 (1-16) transurethral tumor resections were carried out before radical cystectomy (median = 1). Progression-free survival and overall survival of all 230 patients was 54 and 50%, respectively, after 5 years. The best result was a 74% progression-free 5-year survival rate with organ-confined lymph node-negative tumors (n = 106) which was statistically significant (p = 0.0004) compared to the progression-free 5-year survival rate of 50% for non-organ-confined, lymph node-negative tumors (n = 64). Lymph node-positive patients achieved a progression-free survival rate of 21% after 5 years regardless of the tumor infiltration. Patients in group 1 achieved a progression-free 5-year survival rate of 77% and an overall survival rate of 63% after 5 years. In group 2 patients achieved a progression-free survival rate of 51% after 5 years and an overall survival rate of 50%. In the case of primary muscle invasion (group 3), progression-free survival and overall survival were 49 and 46%, respectively, after 5 years. There was no significant difference between groups 2 and 3 with regard to their progression-free or overall survival rates (p > 0.35). However, both groups displayed a significantly poorer progression-free and overall survival rate compared with group 1 (p < 0.01).
CONCLUSION: Our results show that superficial bladder carcinoma with tumor progress to muscle invasion does not have a better prognosis after radical cystectomy than initial muscle-invasive bladder carcinoma. Survival rates in this group can only be improved by singling out patients on the basis of risk factors at an earlier stage and carrying out a cystectomy. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 14963349     DOI: 10.1159/000075962

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  16 in total

1.  [Radical cystectomy in the treatment of bladder cancer always in due time?].

Authors:  M May; K-P Braun; W Richter; C Helke; H Vogler; B Hoschke; M Siegsmund
Journal:  Urologe A       Date:  2007-08       Impact factor: 0.639

2.  Gender-dependent cancer-specific survival following radical cystectomy.

Authors:  Matthias May; Christian Stief; Sabine Brookman-May; Wolfgang Otto; Christian Gilfrich; Jan Roigas; Mario Zacharias; Wolf F Wieland; Hans-Martin Fritsche; Ferdinand Hofstädter; Maximilian Burger
Journal:  World J Urol       Date:  2011-10-09       Impact factor: 4.226

3.  Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?

Authors:  Ahmed F Kotb; Evan Kovac; Wassim Kassouf; Joe Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Darrel Drachenberg; Armen G Aprikian
Journal:  World J Urol       Date:  2012-12       Impact factor: 4.226

4.  Clinical prognostic factors for radical cystectomy in bladder cancer.

Authors:  Seung Hyun Jeon; Sung-Hyun Jeon; Sung-Goo Chang
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

5.  The impact of the two-week wait rule on the diagnosis and management of bladder cancer in a single UK institution.

Authors:  Christopher Blick; David Bailey; Neil Haldar; Amarjit Bdesha; John Kelleher; Asif Muneer
Journal:  Ann R Coll Surg Engl       Date:  2010-01       Impact factor: 1.891

6.  Prognostic factors in radical cystectomy affecting survival.

Authors:  Erdogan Aglamis; Gokhan Toktas; Erdinc Unluer; Cemal Tasdemir; Cavit Ceylan
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

7.  The natural history of secondary muscle-invasive bladder cancer.

Authors:  Guy Hidas; Dov Pode; Amos Shapiro; Ran Katz; Liat Appelbaum; Galina Pizov; Kevin C Zorn; Ezekiel H Landau; Mordechai Duvdevani; Ofer N Gofrit
Journal:  BMC Urol       Date:  2013-05-08       Impact factor: 2.264

8.  MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer.

Authors:  Gongbin Lan; Luoyan Yang; Xubiao Xie; Longkai Peng; Yi Wang
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

9.  Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis.

Authors:  Behfar Ehdaie; Dan Theodorescu
Journal:  Indian J Urol       Date:  2008-01

Review 10.  Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.

Authors:  Mario Pones; David D'Andrea; Keiichiro Mori; Mohammad Abufraj; Marco Moschini; Eva Comperat; Shahrokh F Shariat
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.